4
|
Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VTG, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, Otagiri M, Maruyama T. Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models. J Pharmacol Exp Ther 2014; 352:244-57. [PMID: 25398242 DOI: 10.1124/jpet.114.219493] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Since reactive oxygen species (ROS) derived from Kupffer cells (KC), especially CD68(+) KC, play a key role in the induction of hepatic oxidative stress and injuries, we developed a polythiolated- and mannosylated human serum albumin (SH-Man-HSA), which functions as a novel nanoantioxidant for delivering thiol to CD68(+) KC. In vitro electron paramagnetic resonance coupled with pharmacokinetics and immunohistochemical studies showed that SH-Man-HSA possessed powerful radical-scavenging activity and rapidly and selectively delivered thiols to the liver via mannose receptor (CD206) on CD68(+) cells. SH-Man-HSA significantly improved the survival rate of concanavalin-A (Con-A)-treated mice. Moreover, SH-Man-HSA exhibited excellent hepatoprotective functions, not by decreasing tumor necrosis factor or interferon-γ production that is closely associated with Con-A-induced hepatitis, but by suppressing ROS production. Interestingly, the protective effect of SH-Man-HSA was superior to N-acetyl cysteine (NAC). This could be attributed to the difference in the inhibition of hepatic oxidative stress between the two antioxidants depending on their potential for thiol delivery to the liver. Similar results were also observed for acetaminophen (APAP)-induced hepatopathy models. Flow cytometric data further confirmed that an increase in F4/80(+)/ROS(+) cells was dramatically decreased by SH-Man-HSA. The administration of SH-Man-HSA at 4 hours following a Con-A or APAP injection also exhibited a profound hepatoprotective action against these hepatitis models, whereas this was not observed for NAC. It can be concluded therefore that SH-Man-HSA has great potential for use in a rescue therapy for hepatopathy as a nanoantioxidant because of its ability to efficiently and rapidly deliver thiols to CD68(+)/CD206(+) KC.
Collapse
Affiliation(s)
- Hitoshi Maeda
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Kenshiro Hirata
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Hiroshi Watanabe
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Yu Ishima
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Victor Tuan Giam Chuang
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Kazuaki Taguchi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Akihito Inatsu
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Manabu Kinoshita
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Motohiko Tanaka
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Yutaka Sasaki
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Masaki Otagiri
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Toru Maruyama
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| |
Collapse
|